Skip to main content
We support all people, families and caregivers living with rare diseases, this Rare Disease Day and every day

Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021


September 28, 2021

- “The Muscle to Move to the Clinic” Event Will Highlight Preclinical Data Supporting Advancement of Dyne’s DM1 and DMD Programs Toward Clinical Trials and Anticipated Timelines, and Feature Leading Experts in Both Disease Areas -

WALTHAM, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) --  Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, will host a virtual Research and Development Day on Wednesday, October 13, 2021 from 8:00 – 10:30 a.m. ET. The Muscle to Move to the Clinicevent will focus on Dyne’s co-lead development programs for rare muscle diseases, myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD).

The program will feature presentations, discussion and Q&A with the following speakers:

A live webcast of the event will be available in the Events & Presentations page of the Investors & Media section of Dyne’s website and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit: https://investors.dyne-tx.com/events/event-details/dyne-rd-day.

About Dyne Therapeutics

Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne’s broad portfolio of therapeutic candidates for serious muscle diseases includes programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on TwitterLinkedIn and Facebook.

Contact:

Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com 
857-341-1203



« back to news page